Stay updated with breaking news from Combinedp Gp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New post hoc subgroup analyses from Phase III ARASENS trial in mHSPC show that NUBEQA plus androgen deprivation therapy (ADT) and docetaxel compared to ADT and docetaxel increased overall survival (OS) in specific subgroups with various types of metastatic disease burden and risk1Incidence of adverse events was simi...
FinancialContent fully hosted finance channel
NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall...
Press release content from Business Wire. The AP news staff was not involved in its creation.
Press release content from Business Wire. The AP news staff was not involved in its creation. Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 April 6, 2021 GMT WHIPPANY, N.J.--(BUSINESS WIRE)--Apr 6, 2021-- Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on th...